Literature DB >> 16936434

Repeated implantation is a more effective cell delivery method in skeletal myoblast transplantation for rat myocardial infarction.

Goditha U Premaratne1, Keiichi Tambara, Masatoshi Fujita, Xue Lin, Naoki Kanemitsu, Shinji Tomita, Genichi Sakaguchi, Hiroyuki Nakajima, Tadashi Ikeda, Masashi Komeda.   

Abstract

BACKGROUND: Several clinical trials are underway to determine whether autologous skeletal myoblast transplantation is an effective and safe therapeutic strategy for severe heart failure due to myocardial infarction (MI). It remains unclear whether repeated skeletal myoblast implantation is a feasible and effective cell delivery method for the infarcted myocardium. METHODS AND
RESULTS: Four weeks after a coronary ligation, male syngeneic Lewis rats were assigned to 3 treatment groups: 3 episodes of skeletal myoblasts (6x10(6)) transplantation (group I), a bolus transplantation of myoblasts (18x10(6)) (group II), or culture medium injection (group III). Eight weeks after the first treatment, echocardiography, cardiac catheterization and histological examination were performed to compare the therapeutic effects on left ventricular (LV) systolic and diastolic functions, and the engrafted myoblast volume. Repeated myoblast implantation significantly improved LV function and resulted in significantly larger engrafted volume and LV contractility compared with a bolus transplantation with the same number of myoblasts.
CONCLUSIONS: Repeated skeletal myoblast transplantation is a safe and effective therapeutic strategy for the infarcted myocardium.

Entities:  

Mesh:

Year:  2006        PMID: 16936434     DOI: 10.1253/circj.70.1184

Source DB:  PubMed          Journal:  Circ J        ISSN: 1346-9843            Impact factor:   2.993


  9 in total

Review 1.  Cell therapy for heart failure: a comprehensive overview of experimental and clinical studies, current challenges, and future directions.

Authors:  Santosh K Sanganalmath; Roberto Bolli
Journal:  Circ Res       Date:  2013-08-30       Impact factor: 17.367

2.  Transplantation of elastin-secreting myoblast sheets improves cardiac function in infarcted rat heart.

Authors:  Ayako Uchinaka; Naomasa Kawaguchi; Yoshinosuke Hamada; Shigeru Miyagawa; Atsuhiro Saito; Seiji Mori; Yoshiki Sawa; Nariaki Matsuura
Journal:  Mol Cell Biochem       Date:  2012-06-21       Impact factor: 3.396

Review 3.  Skeletal myoblasts for cardiac repair.

Authors:  Shazia Durrani; Mikhail Konoplyannikov; Muhammad Ashraf; Khawaja Husnain Haider
Journal:  Regen Med       Date:  2010-11       Impact factor: 3.806

4.  Preconditioning of Human Skeletal Myoblast with Stromal Cell-derived Factor-1α Promotes Cytoprotective Effects against Oxidative and Anoxic Stress.

Authors:  Ibrahim Elmadbouh; Husnain Kh Haider; Muhammad Ashraf; Juan-Carlos Chachques
Journal:  Int J Stem Cells       Date:  2011-06       Impact factor: 2.500

Review 5.  Cell-based therapy for heart disease: a clinically oriented perspective.

Authors:  Philippe Menasche
Journal:  Mol Ther       Date:  2009-03-10       Impact factor: 11.454

6.  Repeated Administrations of Cardiac Progenitor Cells Are Markedly More Effective Than a Single Administration: A New Paradigm in Cell Therapy.

Authors:  Yukichi Tokita; Xian-Liang Tang; Qianhong Li; Marcin Wysoczynski; Kyung U Hong; Shunichi Nakamura; Wen-Jian Wu; Wei Xie; Ding Li; Greg Hunt; Qinghui Ou; Heather Stowers; Roberto Bolli
Journal:  Circ Res       Date:  2016-06-30       Impact factor: 17.367

Review 7.  Translational research of adult stem cell therapy.

Authors:  Gen Suzuki
Journal:  World J Cardiol       Date:  2015-11-26

8.  Stromal vascular fraction transplantation as an alternative therapy for ischemic heart failure: anti-inflammatory role.

Authors:  Goditha U Premaratne; Li-Ping Ma; Masatoshi Fujita; Xue Lin; Entela Bollano; Michael Fu
Journal:  J Cardiothorac Surg       Date:  2011-03-31       Impact factor: 1.637

9.  Repetitive transplantation of different cell types sequentially improves heart function after infarction.

Authors:  Schuh Alexander; Alexander Sasse; Simone Konschalla; Andreas Kroh; Marc W Merx; Christian Weber; Elisa A Liehn
Journal:  J Cell Mol Med       Date:  2012-07       Impact factor: 5.310

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.